CN105294450B - 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 - Google Patents

具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 Download PDF

Info

Publication number
CN105294450B
CN105294450B CN201410235747.5A CN201410235747A CN105294450B CN 105294450 B CN105294450 B CN 105294450B CN 201410235747 A CN201410235747 A CN 201410235747A CN 105294450 B CN105294450 B CN 105294450B
Authority
CN
China
Prior art keywords
compound
disease
group
ethyl acetate
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410235747.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105294450A (zh
Inventor
王玉强
刘正
于沛
孙业伟
张在军
张高小
单璐琛
易鹏
吉米·莱雷克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Magpie Pharmaceuticals Co Ltd
Original Assignee
Guangzhou Magpie Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201410235747.5A priority Critical patent/CN105294450B/zh
Application filed by Guangzhou Magpie Pharmaceuticals Co Ltd filed Critical Guangzhou Magpie Pharmaceuticals Co Ltd
Priority to CN202410514632.3A priority patent/CN118239847A/zh
Priority to CN202410514635.7A priority patent/CN118290279A/zh
Priority to AU2015267968A priority patent/AU2015267968B2/en
Priority to PCT/CN2015/000314 priority patent/WO2015180485A1/zh
Priority to CA2950452A priority patent/CA2950452C/en
Priority to JP2017514763A priority patent/JP6639483B2/ja
Priority to EP15798914.6A priority patent/EP3150574B1/en
Priority to ES15798914T priority patent/ES2946987T3/es
Publication of CN105294450A publication Critical patent/CN105294450A/zh
Priority to IL249242A priority patent/IL249242B/en
Application granted granted Critical
Publication of CN105294450B publication Critical patent/CN105294450B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/76—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by nitration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201410235747.5A 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 Active CN105294450B (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202410514632.3A CN118239847A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法
CN202410514635.7A CN118290279A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的盐
CN201410235747.5A CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
PCT/CN2015/000314 WO2015180485A1 (zh) 2014-05-29 2015-05-08 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
CA2950452A CA2950452C (en) 2014-05-29 2015-05-08 Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
JP2017514763A JP6639483B2 (ja) 2014-05-29 2015-05-08 神経保護効用のあるアマンタジン硝酸エステル化合物及びその調製と医療応用
AU2015267968A AU2015267968B2 (en) 2014-05-29 2015-05-08 Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
EP15798914.6A EP3150574B1 (en) 2014-05-29 2015-05-08 Amantadine nitrate compound having a neuroprotective effect and preparation and medical use thereof
ES15798914T ES2946987T3 (es) 2014-05-29 2015-05-08 Compuesto de nitrato de amantadina con efecto neuroprotector y su preparación y uso médico
IL249242A IL249242B (en) 2014-05-29 2016-11-27 Amantadine nitrate compounds with a neuroprotective effect, a process for their preparation and medical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410235747.5A CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410514632.3A Division CN118239847A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法
CN202410514635.7A Division CN118290279A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的盐

Publications (2)

Publication Number Publication Date
CN105294450A CN105294450A (zh) 2016-02-03
CN105294450B true CN105294450B (zh) 2024-05-17

Family

ID=54698036

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201410235747.5A Active CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
CN202410514635.7A Pending CN118290279A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的盐
CN202410514632.3A Pending CN118239847A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410514635.7A Pending CN118290279A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的盐
CN202410514632.3A Pending CN118239847A (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法

Country Status (8)

Country Link
EP (1) EP3150574B1 (enExample)
JP (1) JP6639483B2 (enExample)
CN (3) CN105294450B (enExample)
AU (1) AU2015267968B2 (enExample)
CA (1) CA2950452C (enExample)
ES (1) ES2946987T3 (enExample)
IL (1) IL249242B (enExample)
WO (1) WO2015180485A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397119A (zh) * 2016-04-11 2017-02-15 上海博康精细化工有限公司 一种1，3-金刚烷二乙醇的制备方法
KR101659055B1 (ko) * 2016-05-10 2016-09-23 박소정 에피갈로카테킨 갈레이트 및 3,1-아다만탄디아세트산을 함유하는 알쯔하이머성 치매 치료 및 예방용 약학조성물
CN106344551B (zh) * 2016-08-22 2020-07-28 广州喜鹊医药有限公司 氨基金刚烷单硝酸酯类化合物在制备预防和治疗疾病药物中的应用
CN107412211A (zh) * 2017-08-04 2017-12-01 佛山喜鹊医药有限公司 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
WO2019104020A1 (en) * 2017-11-22 2019-05-31 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat cns disorders
JP7296611B2 (ja) * 2018-08-03 2023-06-23 ビーエイチエヌ株式会社 一酸化窒素産生促進剤
CN109206317B (zh) * 2018-09-12 2021-07-09 青岛海蓝医药有限公司 一种金刚烷胺类硝酸酯衍生物的制备工艺
CN109172560B (zh) * 2018-10-15 2022-08-16 佛山喜鹊医药有限公司 氨基金刚烷硝酸酯类化合物或其药学上可接受的盐在预防和/或治疗肺部疾病中的应用
US20230218548A1 (en) * 2020-03-19 2023-07-13 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections
CN116725997A (zh) * 2022-03-01 2023-09-12 广州喜鹊医药有限公司 氨基金刚烷单硝酸酯类化合物在制药领域中的应用
CN117224520A (zh) * 2023-11-01 2023-12-15 广州喜鹊医药有限公司 (3-氨基-5-乙基金刚烷-1-基)硝酸甲酯及其药学上可接受的盐的医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1400205A (zh) * 2002-08-30 2003-03-05 中国科学院广州化学研究所 美金刚胺盐酸盐的制备方法
CA2426492A1 (en) * 2002-05-31 2003-09-16 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CN1446193A (zh) * 2000-02-22 2003-10-01 全景研究有限公司 作为治疗试剂的氨基金刚烷衍生物
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1125033C (zh) * 2001-08-29 2003-10-22 中国科学院广州化学研究所 美金刚胺盐酸盐的合成方法
US20090088367A1 (en) * 2004-05-10 2009-04-02 Burnham Institute For Medical Research Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia
WO2007065036A2 (en) * 2005-12-02 2007-06-07 Neuromolecular Pharmaceuticals, Inc. Therapeutic conjugates and methods of using same
US9242009B2 (en) * 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1446193A (zh) * 2000-02-22 2003-10-01 全景研究有限公司 作为治疗试剂的氨基金刚烷衍生物
CN1486180A (zh) * 2000-12-07 2004-03-31 纽热莫勒丘乐有限公司 用nmda受体拮抗物治疗神经精神病紊乱的方法
CA2426492A1 (en) * 2002-05-31 2003-09-16 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CN1400205A (zh) * 2002-08-30 2003-03-05 中国科学院广州化学研究所 美金刚胺盐酸盐的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Pharmacology of Aminoadamantane Nitrates;Yuqiang Wang等;《Current Alzheimer Research》;20061231;第3卷(第3期);第201-204页 *

Also Published As

Publication number Publication date
CN105294450A (zh) 2016-02-03
AU2015267968A1 (en) 2016-12-15
CA2950452A1 (en) 2015-12-03
WO2015180485A1 (zh) 2015-12-03
ES2946987T3 (es) 2023-07-31
EP3150574A4 (en) 2017-11-22
AU2015267968B2 (en) 2018-05-17
CA2950452C (en) 2020-03-31
IL249242A0 (en) 2017-02-28
EP3150574A1 (en) 2017-04-05
CN118239847A (zh) 2024-06-25
JP2017521482A (ja) 2017-08-03
IL249242B (en) 2020-03-31
JP6639483B2 (ja) 2020-02-05
CN118290279A (zh) 2024-07-05
EP3150574B1 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
CN105294450B (zh) 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
CN105732412B (zh) 一种用于治疗中风的酰胺类化合物及其制备方法
RS51431B (sr) Beta-kristalni oblik argininske soli perindoprila, postupak za njegovu proizvodnju i farmaceutske smeše koje ga sadrže
US10214478B2 (en) Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
CN109721580B (zh) 3-苯基-7,8-脱氢葡萄藤戊素衍生物、其制法和药物组合物与用途
WO2013004190A1 (zh) 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
CA2949663C (en) Dipicolylamine derivatives and their pharmaceutical uses
WO2015055114A1 (zh) 二苯乙烷衍生物及其应用
CN104147019A (zh) 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用
CN108947859B (zh) 胡黄连素二聚体类似物jja-d0的衍生物或其药学上可接受的盐、制法与用途
CN106188209B (zh) 一种兼具抗肿瘤和抗肿瘤转移活性的二甲双胍偶联物及其应用
JP2023538424A (ja) トリプトリドコンジュゲートおよびその使用
CN107522647B (zh) 含吲哚基团的α-氨基酰胺衍生物及其医药用途
CN105153049B (zh) 一种丹参素酰胺衍生物及其制备方法和用途
CN117618422A (zh) 3-羟基-2-氨基苯并咪唑衍生物在制备防治心肌缺血再灌注损伤的药物中的应用
CN105017034B (zh) 氨基醇类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN104402964B (zh) 闭花木酮的o-(咪唑基)乙基衍生物、制备方法及其用途
CN115504902A (zh) 5-氯水杨酰胺类衍生物、其制备方法及其作为药物的用途
CN113387864B (zh) 一种s-吲哚苯甲酰胺衍生物及其制备方法与应用
CN104277002A (zh) 甘氨酰胺衍生物、中间体、制备方法、药物组合物及应用
CN118619952A (zh) 一种苦豆碱衍生物及其制备方法、药物组合物和用途
CN104800213A (zh) Daphmalenine A衍生物在制备预防或治疗胰腺纤维化药物中的应用
CN108623629A (zh) 一类治疗血栓相关性疾病的化合物、制备方法及其药物用途
CN107721925A (zh) 一种新型乙酰胆碱酯酶抑制剂及其制备方法和应用
NZ726105B2 (en) Dipicolylamine derivatives and their pharmaceutical uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant